MET and non-small cell lung carcinoma: Finally, a recent retrospective analysis conducted on 4233 patients affected by NSCLC with MET exon 14 skipping undergoing NGS both on tumor tissue and on plasma samples, allowed the identification and classification of new variants of this alteration, using the in silico SpliceAI tool for skipping prediction.